SLC5A2 and atrial fibrillation: Our findings may be explained by dapagliflozin's stronger SGLT2 and SGLT1 affinity than empagliflozin, if the anti-AF mechanisms discussed above represent a class effect shared by all SGLT2 inhibitors [27].